Then, the antiviral properties of the three ADAM17 inhibitors were assayed on SARS-CoV-2-infected human lung adenocarcinoma Calu-3 cells after cytotoxicity evaluation with the aim to prove their efficacy to impair the alternative entry pathway of SARS-CoV-2 in host cells. This evidence concerns the gene ADAM17 and lung adenocarcinoma.